via UCL
A new treatment for drug-resistant epilepsy with the potential to suppress seizures ‘on demand’ with a pill, similar to how you might take painkillers when you feel a headache coming on, has been developed by UCL researchers funded by the Wellcome Trust.
The treatment, described in Nature Communications, combines genetic and chemical approaches to suppress seizures without disrupting normal brain function. The technique was demonstrated in rodents but in future we could see people controlling seizures on-demand with a simple pill.
Epilepsy affects around 50 million people worldwide including 600,000 in the UK and around a quarter of cases are resistant to conventional treatments. Many of these cases could be addressed by the new treatment method, which relies on genetic modification of brain cells to make them sensitive to a normally inactive compound.
Read more . . .
The Latest on: Epilepsy treatment
via Google News
The Latest on: Epilepsy treatment
- New seizure predicting mathematical model gives accurate warning to epilepsy patientson February 26, 2021 at 10:02 am
Epilepsy is one of the most common neurological conditions, affecting more than 65 million worldwide. For those dealing with epilepsy, the advent of a seizure can feel like a ticking time bomb.
- Early-warning for seizures could be a game-changer for epilepsy patientson February 26, 2021 at 8:26 am
Epilepsy is one of the most common neurological conditions, affecting more than 65 million worldwide. For those dealing with epilepsy, the advent of a seizure can feel like a ticking time bomb. It ...
- Natco Pharma launches epilepsy treatment drug in Indiaon February 26, 2021 at 12:01 am
The drug maker on Friday announced the launch of brivaracetam tablets under brand Brecita in India. Brivaracetam is indicated towards treatment of epilepsy. The product is developed by UCB Pharma and ...
- Natco Pharma launches epilepsy treatment drug Brivaracetam in Indiaon February 26, 2021 at 12:00 am
Brivaracetam, indicated towards treatment of epilepsy, is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact.
- NATCO launches Brivaracetam tablets, in India, for treatment of epilepsyon February 25, 2021 at 11:51 pm
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the launch of Brivaracetam tablets under brand BRECITA in India. Brivaracetam is indicated towards treatment of epilepsy.Brivaracetam ...
- NATCO Pharma launches Brivaracetam tablets for epilepsy treatment in Indiaon February 25, 2021 at 11:15 pm
Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under brand name Briviact®.
- How a global epilepsy initiative is helping to heal children – Jawebon February 25, 2021 at 9:17 pm
Levi Trowbridge was just 3 days old and newly released from the maternity ward when he went into convulsions last year. Karsha Trowbridge — a first-time mom — said she and her husband, Steve ...
- EEG Data May Help Aid Diagnosis, Treatment of Focal Epilepsyon February 24, 2021 at 4:07 am
An analysis of continuous EEG data suggests seizure onset in focal epilepsy follows circadian, multiday, and annual cycles in findings that could help diagnosis and treatment delivery.
- Sun Pharma to launch Brivaracetam for epilepsy treatment in Indiaon February 23, 2021 at 10:33 pm
Mumbai: Drug major, Sun Pharmaceutical Industries Limited, has recently announced that the company will introduce the complete range of Brivaracetam dosage forms at an affordable price for epilepsy ...
- Sun Pharma to launch range of Brivaracetam drug for epilepsy treatmenton February 23, 2021 at 2:05 am
Sun Pharma's new drug is approved DGCI as an adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.Long-term studies indicate that the ...
via Bing News
